Introduction
Clonality testing is at present an established tool in the diagnosis of malignant lymphomas. Between 5-15% of samples submitted to pathology laboratories which are suspected to be malignant lymphomas can benefit from clonality testing, provided that this is performed in laboratories with sufficient expertise. With the introduction the complete set of primers for the full program of Ig/TR clonality testing by the BIOMED-2 group in 2003, a major step in standardization and quality improvement was set. Many laboratories throughout the world introduced the technology, resulting in questions on pitfalls in technique and the interpretation of the results. NGS-based clonality detection has been introduced in laboratories recently, however guidelines for interpretation need to be established.

EuroClonality/BIOMED-2 workshops
The EuroClonality/BIOMED-2 consortium in 2006 decided to organize annual workshops for laboratories that have introduced clonality testing using the EuroClonality/BIOMED-2 primers and protocols in order to further improve the quality and reliability of the technique and the evaluation of the clonality data in routine practice. Since the vision of EuroClonality is that clonality testing can only be performed reliably when there is close interaction between the clinical molecular biologist and the hematopathologist and/or immunologists (of flow cytometry expert), these workshops are organized for such partners.

The workshops are for a maximum number of 16 persons. Central in the workshop are the discussions of cases that the participants bring themselves. The cases are discussed from the different professionals views (morphology, molecular and clinical context), resulting in interprofessional learning. The cases are used on a hands-on basis, using multiheaded microscopy for pathology evaluation and raw data from clonality tests for interpretation.

We therefore invite persons to the workshop:
- who use the EuroClonality/BIOMED-2 primers and protocols or the EuroClonality NGS-based clonality protocol
- who are able to bring cases for evaluation during the workshop
- who participate as combination of pathology (or flow cytometry) and molecular biology: only a combination of two persons per institute will be accepted for the workshop.

With this background, we are convinced that the workshops are a very fruitful experience that will lead to improved diagnosis of malignant lymphomas and thereby better care for our patients.

Registration
The registration form, including personal details and description of the cases to be presented should be received by the Workshop Secretariat (workshop@euroclonality.org) no later than October 21, 2019. Without submission of cases via the registration form, your registration cannot be accepted. Based on the submission of cases, the registrants will be informed about their provisionally acceptance for the workshop before November 21, 2019. The registration fee for participation in the workshop is €250, which should be paid after provisionally acceptance for the workshop and before December 6, 2019. Participants will be finally accepted only when the registration fee has been received by the Radboudumc before December 6, 2019. Participants will be informed about their final acceptance no later than December 20, 2019. Information on the program, travel to Nijmegen and hotels in Nijmegen will be provided upon acceptance of the registrants.

On behalf of the faculty of the EuroClonality workshop,
Dr. Patricia Groenen, clinical molecular biologist, Radboudumc, also workshop coordinator
Prof. dr. Falko Fend, hematopathologist, University of Tübingen
Dr. Ton Langerak, medical immunologist, Erasmusmc
contact: workshop@euroclonality.org